Zofran inj.+Zofran tab. — Competitive Intelligence Brief

Zofran inj.+Zofran tab. (Zofran inj.+Zofran tab.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 receptor antagonist. Area: Oncology, Gastroenterology, Anesthesia.

marketed 5-HT3 receptor antagonist 5-HT3 receptor Oncology, Gastroenterology, Anesthesia Small molecule

Target snapshot

Zofran inj.+Zofran tab. (Zofran inj.+Zofran tab.) — LG Life Sciences. Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zofran inj.+Zofran tab. TARGET	Zofran inj.+Zofran tab.	LG Life Sciences	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Palonosetron only	Palonosetron only	NYU Langone Health	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Sodium Bicarbonate Powder and ondansetron	Sodium Bicarbonate Powder and ondansetron	Aya Sabry Mohamed Mohamed	marketed	Antacid and antiemetic combination	5-HT3 receptor (ondansetron); non-specific acid neutralization (sodium bicarbonate)
Ramosetron, Aprepitant, Dexamethasone	Ramosetron, Aprepitant, Dexamethasone	Hallym University Medical Center	marketed	5-HT3 antagonist / NK1 antagonist / corticosteroid combination	5-HT3 receptor, NK1 receptor, glucocorticoid receptor
Treatment 2 Ondansetron	Treatment 2 Ondansetron	Hamad Medical Corporation	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Akynzeo solution	Akynzeo solution	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 receptor antagonist class)

1. Helsinn Healthcare SA · 4 drugs in this class
2. LG Life Sciences · 3 drugs in this class
3. University of Malaya · 2 drugs in this class
4. GlaxoSmithKline · 1 drug in this class
5. Hamad Medical Corporation · 1 drug in this class
6. Eye & ENT Hospital of Fudan University · 1 drug in this class
7. Instituto Mexicano del Seguro Social · 1 drug in this class
8. Chongqing University Cancer Hospital · 1 drug in this class
9. Merck Sharp & Dohme LLC · 1 drug in this class
10. MonoSol Rx · 1 drug in this class